The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of GSK’s and Pfizer’s pentavalent vaccines in H1 2024. Beyond this period, market growth will be driven by the uptake of pentavalent vaccines, which could significantly boost coverage for the MenB component by linking the higher coverage rates observed with the booster dose of MenACWY in adolescents (54.4% in 2020) to the suboptimal coverage rates with MenB vaccines (28.4% of 17-year-olds received at least one MenB dose in 2020). However, this will depend on the strength of ACIP recommendations. The pentavalent vaccines would also be more convenient for physicians and patients as they would reduce the total number of doses required during adolescence from four (two MenACWY + two MenB) to three. 

This Datamonitor Healthcare report contains a Disease Analysis module.